Robeco Institutional Asset Management B.V. Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Robeco Institutional Asset Management B.V. lifted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 62.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 448,617 shares of the life sciences company's stock after buying an additional 172,111 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.28% of Illumina worth $59,949,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. TD Private Client Wealth LLC grew its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after buying an additional 141 shares during the period. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after buying an additional 168 shares during the period. Private Trust Co. NA lifted its holdings in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after purchasing an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc bought a new position in Illumina in the third quarter valued at approximately $63,000. Institutional investors own 89.42% of the company's stock.

Illumina Stock Performance

NASDAQ ILMN traded up $1.29 during trading hours on Thursday, hitting $133.01. 1,352,260 shares of the company's stock traded hands, compared to its average volume of 1,694,881. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The business's fifty day moving average price is $139.05 and its two-hundred day moving average price is $135.05. The firm has a market capitalization of $21.10 billion, a P/E ratio of -13.35 and a beta of 1.11. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the company earned $0.33 EPS. The firm's quarterly revenue was down 3.5% on a year-over-year basis. Equities research analysts predict that Illumina, Inc. will post 4.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on ILMN shares. HSBC upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Barclays lifted their price objective on Illumina from $135.00 to $145.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Robert W. Baird raised their price objective on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. UBS Group raised their target price on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley reduced their price objective on Illumina from $156.00 to $150.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $165.63.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.